murine TCR OTI-2A.pMIG II Citations (4)

Originally described in: Generation of T-cell receptor retrogenic mice.
Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DA Nat Protoc. 2006;1(1):406-17. PubMed Journal

---

Articles Citing murine TCR OTI-2A.pMIG II

Articles
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Jenq RR, Hanash AM, Motta AC, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MR. Nat Med. 2017 Jan 9. doi: 10.1038/nm.4258. PubMed
Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation. Miao T, Symonds ALJ, Singh R, Symonds JD, Ogbe A, Omodho B, Zhu B, Li S, Wang P. J Exp Med. 2017 Jun 5;214(6):1787-1808. doi: 10.1084/jem.20160553. Epub 2017 May 9. PubMed
Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases. Lucero OM, Lee JA, Bowman J, Johnson K, Sapparapu G, Thomas JK, Fan G, Chang BH, Thiel-Klare K, Eide CA, Okada C, Palazzolo M, Lind E, Kosaka Y, Druker BJ, Lydon N, Bowers PM. Clin Cancer Res. 2023 May 18:CCR-22-0906. doi: 10.1158/1078-0432.CCR-22-0906. PubMed
CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity. Holling GA, Chavel CA, Sharda AP, Lieberman MM, James CM, Lightman SM, Tong JH, Qiao G, Emmons TR, Giridharan T, Hou S, Intlekofer AM, Higashi RM, Fan TWM, Lane AN, Eng KH, Segal BH, Repasky EA, Lee KP, Olejniczak SH. Cell Mol Immunol. 2024 Mar;21(3):260-274. doi: 10.1038/s41423-024-01124-2. Epub 2024 Jan 18. PubMed

If you have published an article using this material, please email us at to have your article added to this page.